Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome.
During treatment with clomipramine and haloperidol, a 54-year-old depressed woman exhibited a typical neuroleptic malignant syndrome (NMS). Among results of biologic tests performed at least 2 weeks after discontinuation of all psychotropic treatment, the absence of normal growth hormone response after both apomorphine and clonidine challenge tests and increased levels of cerebrospinal fluid homovanillic acid and urinary 3-methoxy-4-hydroxyphenylglycol suggest that NMS may be related to central dopaminergic and possible alpha-noradrenergic receptor blockade.
D002997:Clomipramine / Q000009:adverse effects; D005260:Female; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology / Q000503:physiopathology*; D011941:Receptors, Adrenergic / Q000502:physiology; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D011954:Receptors, Dopamine / Q000502:physiology*
D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D011954:Receptors, Dopamine; D006220:Haloperidol; D002997:Clomipramine